BIONET Corp. Leads Exosome Revolution with Innovative Global R&D and OEM Model 'Exosome Foundry'

Source: BIONET Corp. ( Healthcare+ Expo- booth no.: K104)

BIONET Corp. began investing in exosome research and development in 2002, taking an early lead in the exosome market. Building on this foundation, BIONET Corp. has now launched a pioneering business model, "Exosome Foundry Global R&D OEM," through multinational brand partnerships and a combination of localized and customized services. This model spans 11 business sectors, including healthcare, cosmetics manufacturing, traditional Chinese medicine, pharmaceuticals, and aromatherapy, serving hundreds of clients worldwide.

In collaboration with the medical community, BIONET Corp. has previously utilized neonatal stem cell transplantation to treat blood disorders, metabolic abnormalities, and immune deficiencies, marking the first wave of regenerative medicine achievements in Taiwan. Recognizing the vast potential of exosomes, BIONET Corp. is now extending its expertise into plastic surgery, dermatology, orthopedics, ophthalmology, obstetrics and gynecology, reproductive medicine, and more. The company leverages amniotic fluid exosomes and umbilical cord blood exosomes to support clinical research in areas such as reproductive medicine, premature ovarian failure, thin endometrium, vaginal tightening, stretch marks, postpartum hair loss, skin inflammation, and beyond. Through its next-generation exosome series, BIONET Corp. is launching the second phase of regenerative medicine by offering new value-added services.

To foster the growth of the global exosome industry, BIONET Corp. actively invites international partners to explore various collaboration opportunities and jointly create new business prospects in exosome technology. Through BIONET Corp.'s exclusive Meta Exosome comprehensive solution, the company offers a wide range of exosome R&D and manufacturing services to various industries, both domestically and internationally. Committed to its global exosome R&D center and world-class manufacturing hub, BIONET Corp. provides its partners with high-quality, reliable exosomes at a scale suitable for mass production, setting new standards in the industry.